fenofibrate has been researched along with Heart Failure in 13 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was to observe the effects of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes." | 8.31 | Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes. ( Liu, J; Liu, X; Wang, Y; Zhang, J; Zhou, W, 2023) |
| "Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis." | 5.72 | Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. ( Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F, 2022) |
| "Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes." | 5.42 | Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015) |
| "Inflammation is implicated in chronic heart failure (CHF)." | 5.35 | Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. ( Chen, JW; Huang, WP; Jen, HL; Lin, SJ; Yin, WH; Young, MS, 2009) |
| "This study was to observe the effects of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes." | 4.31 | Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes. ( Liu, J; Liu, X; Wang, Y; Zhang, J; Zhou, W, 2023) |
| "Sprague-Dawley rats were randomly divided into normal control, obesity and fenofibrate group." | 3.78 | High free fatty acids level related with cardiac dysfunction in obese rats. ( Pan, H; Sun, X; Tan, H; Yu, Y, 2012) |
| "For patients with type 2 diabetes at high CV risk but no CKD, fenofibrate therapy added to statin reduced the CV mortality and the rate of fatal and non-fatal CHF." | 2.84 | Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. ( Applegate, WB; Cushman, W; Doumas, M; Lovato, L; Mottle, A; Nylen, E; Papademetriou, V; Punthakee, Z; Tsioufis, C, 2017) |
| "Patients with type 2 diabetes (T2D) have a high risk for developing heart failure (HF), which is associated with poor prognosis." | 1.72 | Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD. ( Falcão-Pires, I; Ferrão, D; Ferreira, JP; Leite-Moreira, A; Neves, JS; Rossignol, P; Saraiva, F; Sharma, A; Vasques-Nóvoa, F; Zannad, F, 2022) |
| "Heart failure is a disease predominantly caused by an energy metabolic disorder in cardiomyocytes." | 1.42 | Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate. ( Cheng, X; Li, P; Luo, S; Pan, C, 2015) |
| "Treatment with fenofibrate, a PPARα agonist, normalized both FA and glucose uptake while reducing LV dilation caused by AR." | 1.42 | Transcriptional Changes Associated with Long-Term Left Ventricle Volume Overload in Rats: Impact on Enzymes Related to Myocardial Energy Metabolism. ( Arsenault, M; Couet, J; Dhahri, W; Drolet, MC; Gascon, S; Lachance, D; Lecomte, R; Rousseau, JA; Roussel, E; Sarrhini, O; Walsh-Wilkinson, E, 2015) |
| "Inflammation is implicated in chronic heart failure (CHF)." | 1.35 | Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. ( Chen, JW; Huang, WP; Jen, HL; Lin, SJ; Yin, WH; Young, MS, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, JP | 1 |
| Vasques-Nóvoa, F | 1 |
| Ferrão, D | 1 |
| Saraiva, F | 1 |
| Falcão-Pires, I | 1 |
| Neves, JS | 1 |
| Sharma, A | 1 |
| Rossignol, P | 1 |
| Zannad, F | 1 |
| Leite-Moreira, A | 1 |
| Morieri, ML | 1 |
| Liu, X | 1 |
| Zhang, J | 1 |
| Zhou, W | 1 |
| Liu, J | 1 |
| Wang, Y | 1 |
| Huang, WP | 2 |
| Yin, WH | 2 |
| Chen, JS | 1 |
| Huang, PH | 1 |
| Chen, JW | 2 |
| Lin, SJ | 2 |
| Dhyani, N | 1 |
| Saidullah, B | 1 |
| Fahim, M | 1 |
| Omanwar, S | 1 |
| Li, P | 1 |
| Luo, S | 1 |
| Pan, C | 1 |
| Cheng, X | 1 |
| Roussel, E | 1 |
| Drolet, MC | 1 |
| Walsh-Wilkinson, E | 1 |
| Dhahri, W | 1 |
| Lachance, D | 1 |
| Gascon, S | 1 |
| Sarrhini, O | 1 |
| Rousseau, JA | 1 |
| Lecomte, R | 1 |
| Couet, J | 1 |
| Arsenault, M | 1 |
| Papademetriou, V | 1 |
| Lovato, L | 1 |
| Tsioufis, C | 1 |
| Cushman, W | 1 |
| Applegate, WB | 1 |
| Mottle, A | 1 |
| Punthakee, Z | 1 |
| Nylen, E | 1 |
| Doumas, M | 1 |
| Jen, HL | 1 |
| Young, MS | 1 |
| Sun, X | 1 |
| Pan, H | 1 |
| Tan, H | 1 |
| Yu, Y | 1 |
| Morgan, EE | 1 |
| Rennison, JH | 1 |
| Young, ME | 2 |
| McElfresh, TA | 1 |
| Kung, TA | 1 |
| Tserng, KY | 1 |
| Hoit, BD | 1 |
| Stanley, WC | 2 |
| Chandler, MP | 2 |
| Labinskyy, V | 1 |
| Bellomo, M | 1 |
| Lionetti, V | 1 |
| Qanud, K | 1 |
| Bigazzi, F | 1 |
| Sampietro, T | 1 |
| Recchia, FA | 1 |
| Shiroshita-Takeshita, A | 1 |
| Brundel, BJ | 1 |
| Burstein, B | 1 |
| Leung, TK | 1 |
| Mitamura, H | 1 |
| Ogawa, S | 1 |
| Nattel, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients[NCT06155331] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for fenofibrate and Heart Failure
| Article | Year |
|---|---|
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofib | 2017 |
12 other studies available for fenofibrate and Heart Failure
| Article | Year |
|---|---|
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glucose; Heart Failure; Hum | 2022 |
Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional Hope?
Topics: Diabetes Mellitus, Type 2; Fenofibrate; Heart Failure; Humans; Hypolipidemic Agents | 2022 |
Effect of fenofibrate on blood lipid, sICAM-1, ET-1 and prognosis in chronic heart failure patients complicated with diabetes.
Topics: Chronic Disease; Diabetes Mellitus; Fenofibrate; Heart Failure; Hospitalization; Humans; Lipids | 2023 |
Fenofibrate attenuates doxorubicin-induced cardiac dysfunction in mice via activating the eNOS/EPC pathway.
Topics: Animals; Cardiomyopathies; Cardiotoxicity; Disease Models, Animal; Doxorubicin; Endothelial Progenit | 2021 |
Fenofibrate ameliorates neural, mechanical, chemical, and electrical alterations in the murine model of heart failure.
Topics: Animals; Baroreflex; Blood Pressure; Disease Models, Animal; Electrocardiography; Energy Metabolism; | 2019 |
Modulation of fatty acid metabolism is involved in the alleviation of isoproterenol-induced rat heart failure by fenofibrate.
Topics: Animals; Cells, Cultured; Energy Metabolism; Fatty Acids; Fenofibrate; Heart Failure; Hypolipidemic | 2015 |
Transcriptional Changes Associated with Long-Term Left Ventricle Volume Overload in Rats: Impact on Enzymes Related to Myocardial Energy Metabolism.
Topics: Animals; Aortic Valve Insufficiency; Cardiac Volume; Disease Models, Animal; Energy Metabolism; Feno | 2015 |
Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study.
Topics: Aged; Blotting, Western; Cell Adhesion; Chronic Disease; Female; Fenofibrate; Heart Failure; Humans; | 2009 |
High free fatty acids level related with cardiac dysfunction in obese rats.
Topics: Angiotensin II; Animals; Biomarkers; Diet, High-Fat; Fatty Acids, Nonesterified; Fenofibrate; Heart | 2012 |
Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure.
Topics: Animals; Ceramides; Dietary Fats; Disease Models, Animal; Feeding Behavior; Fenofibrate; Heart Failu | 2006 |
Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
Topics: Acyl-CoA Dehydrogenases; Animals; Blood Pressure; Cardiac Pacing, Artificial; Cholesterol; Dogs; Ele | 2007 |
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.
Topics: Actins; Animals; Anti-Inflammatory Agents; Atrial Fibrillation; Biomarkers; Cardiac Pacing, Artifici | 2007 |